SYNGENE Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹875 Cr
verified against source
Revenue YoY
11%
reported change
EBITDA
₹206 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene delivered a strong Q1 FY26 with revenue from operations at ₹875 crore, up 11% YoY (7% in constant currency), driven by continued momentum in research services which comprised 67% of sales. EBITDA grew 21% YoY to ₹206 crore with margins expanding 200bps to 24% on operational efficiency and favorable business mix. PAT before exceptional items was ₹87 crore, up 59% YoY, though normalized PAT growth was 47% YoY after adjusting for a one-time gratuity fund tax benefit. Key operational milestones include the inauguration of a state-of-the-art peptide laboratory and Unit 3 biologics facility becoming operational with a GMP clinical batch delivered. Management reiterated FY26 guidance for mid-single-digit reported growth (underlying early teens) and mid-20s EBITDA margins, citing confidence from Q1 progress. Risks include biotech funding uncertainty, ongoing inventory adjustments in commercial biologics, and macro headwinds from US tariffs affecting big pharma clients.
Colored figures show movement against the previous available record.
Guidance to track
- Management reaffirmed guidance for mid-single-digit reported revenue growth, adjusting for client inventory rebalancing in commercial biologics manufacturing. Underlying business expected to grow in early teens.
- Full year EBITDA margins expected in mid-20s, with some degrowth impact due to increased depreciation as Unit 3 and Bayview facilities come online. Q1 margins at 24% support this trajectory.
- US-based Bayview facility revalidation and integration efforts on track; expect to operationalize in second half of FY26. Facility offers versatility with three discrete suites and has generated healthy interest from potential customers.
- Normalized effective tax rate expected around 24% for FY26. Q1 reported ETR of 14% included favorable one-time tax adjustment on gratuity fund transfer; normalized ETR was 21%.
Risks flagged
- US biotech funding has not stabilized or returned to pre-pandemic levels, creating uncertainty for early-stage discovery services. While large pharma interest remains healthy, biotech represents an important input stream that could impact pilot pipeline conversion.
- Client inventory rebalancing in the biologics commercial manufacturing business is ongoing, with more impact expected in coming quarters. This was factored into FY26 guidance but represents a headwind to reported growth.
- Large pharma clients continue to undergo internal restructuring, creating uncertainty around outsourcing decisions and potential delays in project approvals or launches. Monitored closely by management.
- Management declined to provide specific timelines for renewal discussions on dedicated center contracts, including the Amgen contract expiring in 2026. While historically relationships span decades, the opacity on specific renewal status represents unquantified risk.
Key quotes
- We framed our guidance at the end of last year, and we are encouraged by the positive start and the growth in Q1. We're twelve weeks into the year, and it's just too early for us to make adjustments at this stage. As the quarters unfold, we will revise or refine as we see it.
- When we had guided towards single digit growth, there are a couple of things that we had called out. One, we were seeing an inventory adjustment that would come through the year on account of commercial manufacturing in our biologics plant. That is still to come.
- Biotech funding... plays into early stage biotech companies, represent one of the inputs into our discovery services. But these pilots are one source of input. We continue to have a healthy pipeline from multinational and mid-sized biopharma companies who are looking to externalize some of their discovery services.
Research modules